Background: Inactivation of p16 by methylation of CpG islands is a frequent early event in human cancers, including papillary thyroid carcinoma (PTC). This study was to observe the methylation status of the p16 gene in papillary thyroid carcinoma (PTC) and its correlation with clinical parameters. Methods: Methylation-specific PCR (MSP) was used to analyze the methylation status of the p16 gene in 74 PTCs and 21 adjacent normal thyroid tissues. Results: Hypermethylation of p16 gene was observed in 27.0% (20/74) of PTC. None of the normal thyroid tissues was methylated, when compared to the PTCs ( p < 0.05). There was no marked relationship between the methylation of p16 gene and the patients' age, gender, size of cancer, histological subtypes and occurrence of recurrent disease ( p > 0.05). The methylation of p16 gene was positively associated with metastasis, a high AMES (age, metastasis to distant sites, extrathyroidal invasion, size) risk group ( p < 0.05) and advanced pathological tumorelymph nodeemetastasis stages. Conclusion: The methylation of the p16 gene, one event of significance in molecular biology, was common and correlated with biological metastasis and histological features in PTC, and may be involved in thyroid tumorigenesis and aggressiveness.
Introduction
The P16 suppressor gene is one of the most commonly studied candidates in the pathogenesis of human neoplasia, belonging to a class of cyclin-dependent kinase (CDK) inhibitory proteins. It binds specifically to CDK 4 and inhibits the catalytic activity of the CDK-cyclin D complex, a key regulator of the G1 checkpoint of the cell cycle. 1 There are three main mechanisms that alter the p16 gene: homozygous deletion, promoter hypermethylation, and, very rarely, point mutations. 2 In particular, promoter hypermethylation of CpG islands has been shown to be an epigenetic change resulting in loss of function of responsive genes involved in cell cycle regulation and DNA repair. Methylation of p16 CpG islands silences transcription of this gene. 3 It has been observed that in primary gastric carcinoma (GC), the frequency of p16 inactivation by homozygous deletions ranges 0e9%, by mutation 0e2%, while by methylation 32e42%, 4e10 which suggests that methylation is a major mechanism for p16 inactivation in GC. Moreover, p16 methylation is significantly correlated with progression of GCs. 11 In addition, it was reported that the p16-methylated cells could have an advantage in progression and metastasis in non-small-cell lung cancers. 12 Papillary thyroid carcinoma (PTC) is the most common malignancy originating in the thyroid gland, and accounts for about 60% of adult thyroid carcinomas and 100% of childhood thyroid carcinomas. With respect to gene alterations in carcinogenesis, RET, BRAF, and RASSF1A genes have been noted in a substantial number of patients with PTC. 13, 14 However, our understanding of the pathway toward carcinogenesis in PTC is incomplete, in part because abnormalities in the control of cell cycle checkpoints are common in carcinogenesis. As for p16 inactivation in PTC, some previous studies 15e18 have demonstrated that hypermethylation of the 5 0 CpG island of p16 are common and critical events, responsible for the development of PTC, rarely by mutation. Moreover, Lam et al. 18 reported p16 mRNA or p16 protein was detected in 77% and 89% of PTC, respectively, indicating that the overexpression of p16 rather than the loss of its protein contributes to the pathogenetic mechanism of PTC. These findings imply that methylation of CpG islands of p16 may also play a role in increasing the occurrence and metastatic potential of PTC as an epigenetic event during disease progression.
In this study, a total of 74 PTC tissues and 21 adjacent normal thyroid tissues were evaluated using methylationspecific PCR (MSP) to assess hypermethylation in the p16 gene implicated in regulatory processes, revealing a progressive increase of p16 alterations within thyroid tumorigenesis and from primary carcinomas to metastatic lesions. The results showed statistically significant correlations between p16 methylation and certain clinical features of the tumors.
Methods

PTC samples and cell lines
A total of 74 PTCs including 37 primary and 37 metastatic tumors, and 21 adjacent normal thyroid tissues from primary (10 cases) and metastatic (11 cases) tumors were obtained from patients from the Beijing Cancer Hospital by surgical resection (with their informed consent) between 2004 and 2010 and were stored at À70 C until use. Treated patients received routine clinical and sonographic follow-up every 3e6 months. The follow-up period ranged from 6 months to 7 years 9 months (mean, 21 months). During the follow-up period, cervical lymph node involvement was verified in five patients (6.76%). Distant metastases (bone or lung) developed in two patients (2.63%). All clinical samples and histopathological information for each case were obtained according to approved institutional guidelines. A tumor risk profile was assigned according to commonly adopted AMES (age, metastasis to distant sites, extrathyroidal invasion, size) risk group stratification and the Union for International Cancer Control (UICC) pTNM (pathological tumorelymph nodeemetastasis) staging.
Human gastric cancer cell line AGS and MGC803, serving as p16 promoter methylation and unmethylation, were cultured in RPMI 1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco) at 37 C with 5% CO 2 .
This study was approved by the Research and Ethical Committee of Peking University School of Oncology.
DNA extraction
DNA was extracted from frozen thyroid tissue and tissue culture cells by standard sodium dodecyl sulfate (LookChem, Shijiazhuang, China)/proteinase K (SBS Genetech, Beijing, China) digestion followed by organic extraction and ethanol precipitation.
Sodium bisulfite treatment
One microgram of genomic DNA was denatured in 0.2 M NaOH (Guide Chem, Beijing, China) for 10 minutes at 37 C. The denatured DNA was diluted in 500 mL of freshly prepared solution of 10 mM hydroquinone (Yaou Chemicals Co. Ltd, Taiyuan, China) and 3 M sodium bisulfite (JinRuiQi Chemical Co. Ltd, Tianjin, China) and incubated for 16 h at 50 C. After incubation, the DNA sample was desalinized through a column (Wizard DNA Clean-Up System; Promega, Madison, WI, USA), treated with 0.3 M NaOH for 10 minutes at room temperature, and precipitated with ethanol. The bisulfite-modified genomic DNA was resuspended in 40 mL of H 2 O and stored at À20 C.
Methylation-specific PCR of p16
DNA methylation status for all cell lines and PTC were determined by MSP, which is sufficiently sensitive to detect a single methylated allele among 1000 unmethylated ones and, therefore, may be the most appropriate methodology for identifying DNA methylation patterns within CpG islands of p16. MSP distinguishes unmethylated from methylated alleles based on sequence changes produced after bisulfite treatment of DNA, which converts only unmethylated cytosine to uracil, and subsequent PCR using primers designed for either methylated or unmethylated DNA.
Therefore, we utilized MSP to analyze the methylation status of the bisulfite-modified p16 CpG islands. Both the p16-M and p16-U primer sets for the methylated p16 CpG islands. 19 were 5 0 -TTATTAGAGGGTGGGGCGGATCGC-3
0 (sense p16-U), and 5 0 -CAACCCCAAACCACAACCATAA-3 0 (antisense p16-U). The PCR products of p16 CpG islands were amplified by hot-start PCR. HotStarTaq DNA polymerase (QIAGEN GmbH, Hilden, Germany) was used. Thermal cycler conditions were denaturing at 95 C for 15 minutes, amplified for 35 cycles (95 C for 40 seconds, 62 C for 40 seconds, 72 C for 40 seconds), with extension at 72 C for 10 minutes. The reaction mixture (20 mL) contained about 10 ng of templates, 4 pmol of each primer, 4 nmol of dNTP, and 1 unit of HotStarTaq DNA polymerase. Distilled water and genomic DNA of the p16 unmethylated MGC803 cells were used as template for negative control. Genomic DNA of p16-methylated AGS was used as positive control. These controls were used in each individual MSP experiment. The methylated p16 MSP products could be amplified with the p16-M in the positive control, but not in the negative controls. The MSP products were run on 2% agarose gel.
Statistical evaluation
Statistical analysis was carried out using SPSS 11.5 (SPSS Inc., Chicago, IL, USA). Categorical variables were plotted in contingency tables and evaluated using Fisher's exact test. Mean methylation index between analyzed groups was evaluated using the independent t test. All reported p-values are two-sided and considered significant at p < 0.05.
Results
To determine the role of p16 gene inactivation in the pathogenesis of PTCs, the methylation status of p16 CpG islands, which have been found to play a role in tumorigenesis, were analyzed by MSP in 95 tissues including 74 PTCs and 21 normal tissues. As shown in Fig. 1, p16 promoter methylation was noted in 20 of 74 (27%) tumor tissues, but 21 normal tissues did not show any evidence of p16 promoter methylation ( p ¼ 0.005). The clinicopathological features of these tumors were studied in reference to both AMES criteria and pTNM staging system (Table 1 had p16 methylation in their PTC more frequently, compared with those having less advanced disease. However, the difference did not reach statistical significance ( p ¼ 0.075, Fisher's test).
Discussion
The mechanistic association between aberrant promoter region CpG island methylation and transcriptional silencing is complex. In normal cells, most promoter region CpG islands are unmethylated and maintain a transcriptionally favorable local chromatin configuration. 20 Aberrant methylation of these normally unmethylated CpG islands is associated with underacetylated histones and a shift to a transcriptionally repressive chromatin structure. 21, 22 In our study, we investigated the level of promoter hypermethylation of p16 gene in PTC as compared with those levels in adjacent normal tissues. Results showed that the frequency of p16 methylation in PTC was 27% ( p < 0.05), which suggests that it is a frequent molecular biology occurrence in PTC, probably resulting in tumorigenesis as an active induced factor. At the same time, to understand better the role of promoter hypermethylation status in the natural history of PTC and as a molecular predictor of disease progression, we evaluated the association between gene hypermethylation and clinicopathological characteristics of primary PTC. It was concluded that p16 promoter methylation were often associated with a high AMES risk group and advanced pTNM stages but had no correlation to sex or disease recurrence.
In addition, a much higher positive rate and average proportion of methylated p16 were detected in PTC (n ¼ 37) with metastases (local or distant) than PTC (n ¼ 37) without metastases. This does not exclude the possibility that the primary tumor was heterogenous and that only a small subpopulation of the primary tumor cells metastasized.
Another explanation involves the generation and subsequent selection of new subclones within the metastases or their independent origin from the primary tumor. 23 This heterogeneity may increase the ability of the tumor to face different environmental challenges, and may explain the poor prognosis of metastatic PTC. It is likely that, the methylation possibly transforming to metastatsis is a feature of selective advantage in tumor progression.
Inactivation of p16INK4a by methylation is a common and early event in the development of cancer.
24e26 Aberrant methylation of p16 may be analogous to homozygous deletion, leading to lack of p16 expression and a selective growth advantage to tumor cells. 3, 27 Progressive methylation of the p16 gene has been reported in early lesions of squamous carcinomas of the lung 28 and in 31% of cervical cancers. 29 The highest frequency of p16 inactivation (30e40%) has been reported in tumors of the colon, lung, brain, esophagus, stomach, pancreas, and in 48% of lymphomas. 30 The incidence of p16 promoter hypermethylation in PTC have also been reported, with frequencies reported to be three (25%) of 12, four (33%) of 12, seven (42%) of 16 and 18 (41%) of 44 in four studies.
15e18 Here, we detected methylation of p16 in 27% of thyroid carcinomas, which is consistent with 25% frequency noted for silencing in a similar study. 15 In conclusion, these results show that p16 promoter hypermethylation in PTC appears to be associated with tumor risk profile, invasive tumor behavior and development of metastases. However, the patterns of CpG island hypermethylation in primary and metastatic PTC are complex. Hypermethylation events present in both the primary and metastatic tumors may be from events that were present very early in the development of the primary tumor. Further tumor evolution may proceed differently in various regions, either by random chance or by selection because of different microenvironments. This may result in the formation of many unique subpopulations with regard to methylation within the primary tumor. In other words, the lack of hypermethylation seen in the metastatic PTC at loci may be previously methylated in the primary tumor. Therefore, it is strongly suggested that the relationship between those patterns in any one patient may require a more sophisticated explanation than a simple accumulation of changes. 
